Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) – Research analysts at Cantor Fitzgerald raised their FY2022 EPS estimates for Alaunos Therapeutics in a research note issued on Tuesday, January 10th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings per share of ($0.17) for the year, up from their previous estimate of ($0.18). The consensus estimate for Alaunos Therapeutics' current full-year earnings is ($0.16) per share. Cantor Fitzgerald also issued estimates for Alaunos Therapeutics' FY2023 earnings at ($0.16) EPS.

Separately, Wells Fargo & Company reiterated an "overweight" rating and issued a $3.00 price objective on shares of Alaunos Therapeutics in a report on Tuesday, October 4th.

Alaunos Therapeutics Price Performance

Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. The firm had revenue of $2.91 million during the quarter.

Insider Buying and Selling

In other Alaunos Therapeutics news, Director Robert W. Postma bought 750,000 shares of Alaunos Therapeutics stock in a transaction that occurred on Tuesday, November 29th. The stock was purchased at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the completion of the acquisition, the director now owns 5,000,000 shares of the company's stock, valued at approximately $3,250,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.90% of the stock is currently owned by insiders.

Institutional Trading of Alaunos Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Discovery Capital Management LLC CT bought a new stake in Alaunos Therapeutics during the second quarter worth approximately $17,515,000. Laurion Capital Management LP acquired a new position in Alaunos Therapeutics in the 2nd quarter worth approximately $5,319,000. JPMorgan Chase & Co. acquired a new position in Alaunos Therapeutics in the 2nd quarter worth approximately $5,231,000. State Street Corp boosted its stake in Alaunos Therapeutics by 268.3% in the 3rd quarter. State Street Corp now owns 3,178,423 shares of the company's stock worth $5,467,000 after purchasing an additional 2,315,397 shares during the period. Finally, Millennium Management LLC acquired a new position in Alaunos Therapeutics in the 2nd quarter worth approximately $2,690,000. 34.36% of the stock is currently owned by institutional investors.

Alaunos Therapeutics Company Profile

(Get Rating)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.

See Also

• Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
• MarketBeat: Week in Review 01/09-01/13
• JPMorgan Chase Falls As Banks Brace For Recession
• Why is the Bed Bath & Beyond Stock Price up 261%?
• Roku Stock Price is Trending, Here's Why
• Carvana Stock Rally, Here's What You Need to Know

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.